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Abstract
Introduction: Synovial hyperplasia is a main feature of rheumatoid arthritis pathology that leads to cartilage and bone 
damage in the inflamed joints. Impaired apoptosis of resident synoviocytes is pivotal in this process. Apoptosis 
resistance seems to involve defects in the extrinsic and intrinsic apoptotic pathways. The aim of this study was to 
investigate the association of PI3Kinase/Akt and the mitochondrial apoptotic pathway in the resistance of rheumatoid 
arthritis (RA) fibroblast like synovial cells (FLS) to Fas-mediated apoptosis.
Methods: Apoptosis was assessed by ELISA quantification of nucleosomal release, Hoechst staining and activated 
caspase-3/7 measure in cultured RA FLS stimulated with anti-Fas antibody. Two Phosphoinositol-3-kinase/protein 
Kinase B (PI3 Kinase) inhibitors, Wortmannine and LY294002, were used before anti-Fas stimulation. Proapoptotic BH3 
interacting domain death agonist (Bid) was suppressed in RA FLS by small interfering RNA (siRNA) transfection. Bid was 
overexpressed by transfection with the pDsRed2-Bid vector. Phosphorylated Akt, caspase-9, and Bid expression were 
analysed by western blot.
Results: PI3 kinase inhibition sensitizes RA FLS to Fas-induced apoptosis by increasing cleavage of Bid protein. Bid 
suppression completely abrogated Fas-induced apoptosis and Bid overexpression highly increased apoptotic rate of 
RA FLS in association with cleavage of caspase-9.
Conclusions: In RA FLS, phosphorylation of Akt protects against Fas-induced apoptosis through inhibition of Bid 
cleavage. The connection between the extrinsic and the intrinsic apoptotic pathways are critical in this Fas- mediated 
apoptosis and points to PI3Kinase as potential therapeutic target for RA.
Introduction
In rheumatoid arthritis (RA) joints synovial hyperplasia and
inflammatory cell infiltration lead to progressive destruc-
tion of cartilage and bone. Although the mechanisms under-
lying synovial hyperplasia are not completely known,
accumulating evidence suggests that alterations in the apop-
tosis of synoviocytes are pivotal [1-3].
Interestingly, RA fibroblast-like synoviocytes (FLS)
express death receptors; yet, they are relatively resistant to
FasL, TNF, and tumor necrosis (TNF)-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis [3-5]. This
resistance has been related to high expression of anti-apop-
totic molecules such as Fas-associated death domain-like
IL1 beta-converting enzyme-inhibitory protein (FLIP)
[6,7], sentrin-1 [8,9], Bcl-2 [10], Mcl-1 [11], and constitu-
tive activation of Akt [12-14].
Apoptosis is a process highly regulated and crucial in
many physiological situations, and could involve two main
pathways; the extrinsic, by activation of death receptors
(Fas, TNF-RI), and the intrinsic or mitochondrial pathway.
In the extrinsic pathway, FasL, TNF, and TRAIL ligation
leads to recruitment of Fas-associated via death domain
(FADD) and procaspase-8, which form the death inducing
signaling complex (DISC), where caspase-8 is activated. In
turn, caspase-8 activates caspase-3, which causes DNA
fragmentation and cell death. The mitochondrial pathway is
induced by hypoxia, cytotoxic drugs and growth factor
deprivation leading to liberation of cytochrome c (cyt c)
and Apaf-1-mediated activation of the caspase-9 [15-17].
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This pathway is tightly regulated by members of the Bcl-2
family with anti-apoptotic function, such as Bcl-2, Bcl-xL,
Bcl-w, Mcl-1, and A1, which prevent mitochondrial mem-
brane permeability and release of cyt c. In contrast, other
Bcl-family members, such as Bax, Bak, Bok, BH3 interact-
ing domain death agonist (Bid), Bad, Bim, and Puma, are
pro-apoptotic and promote mitochondrial membrane per-
meability [18]. In some cell types, named type II cells, the
two apoptotic pathways are connected through the cleavage
of Bid by activated caspase-8. Truncated Bid translocates to
the mitochondria causing release of cyt c and cell death
[19]. In contrast, in type I cells, death-receptor induced
apoptosis is independent of Bid [19]. It seems that both the
intrinsic and extrinsic apoptotic pathways are involved in
arthritis development. There is much evidence implicating
the extrinsic pathway [review in ref [20] and [21]]. How-
ever, support for the role of the intrinsic pathway is scant,
although very convincing. For example, mice lacking Bim
[22] or Bid [23] develop a severe synovial inflammation
and bone destruction in an arthritis model. Also, evidence
suggests that RA FLS are type II cells [24]. Therefore, it is
necessary to investigate the relevance of the intrinsic path-
way and its connection with the extrinsic pathway in the
FLS resistance to apoptosis.
RA FLS typically show Akt activation that could contrib-
ute to the relative resistance to apoptosis by unknown
mechanisms. Akt/PKB is a Ser/Thr protein kinase impli-
cated in inhibition of apoptosis and stimulation of cellular
growth in several tissues by mechanisms including phos-
phorylation of the pro-apoptotic proteins Bad [25] and Bax
[26], and suppression of pro-apoptotic proteins such as Bim
and PUMA, through phosphorylation of the forkhead path-
way [27]; favouring the anti-apoptotic effect of Mdm2 on
p53 [28]; and inhibition of cleavage of Bid protein [29,30].
The aim of this study was to investigate the connection of
the death receptor stimulation with the intrinsic pathway in
the apoptosis of the type II cells RA FLS, and to analyse the
possible relation between constitutively activated phospho-
inositol-3 (PI3) kinase/Akt and the mechanisms of resis-
tance to Fas-mediated apoptosis.
Materials and methods
Fibroblast-like synoviocytes
FLS from 11 patients with RA were obtained at the time of
synovectomy or total joint replacement. All RA patients
fulfilled the American College of Rheumatology 1997 cri-
teria for RA classification [31]. All patients gave informed,
written consent. The study was performed according to the
recommendations of the Declaration of Helsinki and with
the approval of the Comité Etico de Investigación Clínica
de Galicia. Synovial tissue was minced and incubated with
10 μg/ml collagenase in serum-free DMEM (Gibco Invitro-
gen, Barcelona, Spain) for three hours at 37°C. After diges-
tion, FLS were filtered through a nylon cell strainer (BD
Falcon, Franklin Lakes, NJ 07417 USA), washed exten-
sively with DMEM, and cultured in DMEM supplemented
with 10% v/v FCS (Gibco Invitrogen, Barcelona, Spain),
1% penicillin-streptomycin (Gibco Invitrogen, Barcelona,
Spain) and 1% L-glutamine (Sigma, St Louis, MO, USA) in
a humidified 5% carbon dioxide atmosphere. Adherent
cells were trypsinized and splited in a 1:3 ratio once the
cells were 80 to 90% confluent. FLS from passages three to
eight were used.
Small interfering RNA transfection in FLS
Bid small interfering RNA (siRNA), a pool of four target-
specific 19 nucleotide siRNAs, and non-silence control
siRNA, a pool of four non-targeting siRNAs, were pur-
chased from Dharmacon (Fisher Bioblock Scientific, Stras-
bourg, France). siRNA transfections were performed as
described elsewhere [32]. Briefly, RA FLS at 80 to 90%
confluence were transiently transfected with siRNA (200
nM) in Opti-MEM I (Gibco Invitrogen, Barcelona, Spain)
using 1.25 μg/ml DharmaFECT 1 (Dharmacon, Fisher Bio-
block Scientific, Strasbourg, France). Bid suppression was
analysed by western blot. Experiments were performed 48
hours after transfections.
pDsRed2-Bid Vector transfection in FLS
pDsRed2-Bid Vector, a 5.3 Kb mammalian expression vec-
tor that encodes a fusion of Discosoma sp red fluorescent
protein (DsRed2) and Bid, and the empty pDsRed2 vector,
were purchased from Clontech (Mountain View, CA, USA).
RA FLS at 60% confluence were transiently transfected
with 0.5 μg pDsRed2-Bid vector or pDsRed2 vector in
Opti-MEM I (Gibco Invitrogen, Barcelona, Spain) using 4
μg/ml Lipofectamine (Gibco Invitrogen, Barcelona, Spain)
and 9 μg/ml Plus Reagent (Gibco Invitrogen, Barcelona,
Spain). Bid expression was analysed by western blot and
immunofluorescence assays. Experiments were performed
48 hours after transfections.
Apoptosis and cell death assays
RA FLS (3 × 103) were cultured in 96-well plates with
DMEM and 5% FCS. Forty-eight hours after transfection,
cells were treated for one hour with 10 μM LY294002 (LY),
1 μM wortmannin (Wort; Sigma, St Louis, MO, USA) or 10
μM Z-LE(OMe)HD(OMe)-FMK (Calbiochem-Merck
KGaA, Darmstadt, Germany) and then incubated for 12
hours either with 1 μg/ml of human anti-Fas, clone 11 (Cell
Signaling, Beverly, MA, USA) or with 100 ng/ml of mem-
brane bound Fas ligand (memFasL, Millipore, Molsheim,
France), when indicated. Apoptosis was determined by
quantifying mono- and oligonucleosomal DNA using the
Cell Death Detection ELISA kit (Roche Diagnostics, India-
napolis, IN, USA) as previously described [14]. Apoptosis
was confirmed by Hoechst staining and measure of acti-
vated caspase-3/7 by the Caspase-Glo 3/7 assay (PromegaGarcía et al. Arthritis Research & Therapy 2010, 12:R33
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Biotech Ibérica, S.L., Spain). RA FLS (104) were cultured
either on 24-well plates (Hoechst assay) or 96-well plates
(Caspase-Glo 3/7 assay), treated for one hour with 1 μM
Wort or 10 μM LY and then incubated for 12 hours with 1
μg/ml of human anti-Fas. After incubation, plates were
stained with 10 μg/ml Hoechst 33258 (Sigma, St Louis,
MO, USA), fixed with 4% paraformaldehyde and the cells
were examined by fluorescence microscopy. For activated
caspase-3/7 analysis, cells were incubated for one hour with
reconstituted Caspase 3/7-Glo reagent and then, the lumi-
nescence signal generated after cleavage of DEVD-amino-
luciferin substrate by caspase 3/7, was measured using a
Fluostar OPTIMA microplate reader (BMG Labtech,
Offenburg, Germany).
Western blot analysis
After siRNA transfections, RA FLS (8.5 × 104) were cul-
tured in six-well plates, treated for one hour with 1 μM
Wort and then stimulated with human anti-Fas 1 μg/ml for 3
or 12 hours. Cells were washed twice with ice-cold PBS,
and protein was extracted using lysis buffer (50 mM Tris
HCl [pH 7.5], 250 mM NaCl, 1% Triton X-100, 30 mM
NaPO, 5 mM EDTA (pH 8.0), 100 mM NaF, 1 mM
Na3VO4, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1 mM
phenylmethylsulfonyl fluoride). The protein concentrations
in the extracts were determined using the Qubit fluorometer
(Invitrogen, C/Garrotxa 10-12, Prat de Llobregat, Barce-
lona, Spain) according to the manufacturer's protocol.
Whole cell lysates (40 to 50 μg of protein) were fraction-
ated by Tris-glycine buffered 10% SDS-PAGE and trans-
ferred to polyvinylidene fluoride (PVDF) membrane
(Hybond-P, Amersham Biosciences, Little Chalfont, UK).
The membranes were blocked with Tris buffered saline and
0.1% Tween-20 (TBST) containing 5% non-fat milk for
two hours at room temperature, followed by incubation
with antibody to phospho-Akt, Akt, Bid, Caspase-9 (Cell
Signalling, Beverly, MA, USA) or β-actin (Sigma, St Louis,
MO, USA) overnight at 4°C. After washing with TBST, the
membrane was incubated with horseradish peroxidase-con-
jugated secondary antibody (Santa Cruz, Bergheimer Str
89-2, Heidelberg, Germany for one hour at room tempera-
ture. Immunoreactive protein was detected with Immobil-
ion western (Milipore, MA, USA).
Statistical analysis
Differences between experimental groups were assessed by
Wilcoxon matched-pairs test. P values less than 0.05 were
considered significant.
Results
Regulation of Fas-mediated apoptosis in RA FLS by Akt
RA FLS from six patients were pre-treated for one hour
with Wort or LY, and stimulated thereafter with Fas-anti-
body for 12 hours. Apoptosis of RA FLS was determined
by analysis of nucleosomal release, Hoechst staining and
activated caspase-3/7 measurement. As a positive control
we analysed the nucleosomal release after anti-Fas stimula-
tion in Jurkat cells. Mean DO492 nm was 0.93 versus a
mean of 0.13 observed in the six RA FLS, confirming the
relative resistance of these latter cells to Fas-induced apop-
tosis.
In RA FLS, anti-Fas stimulation induced significant
apoptosis compared with the basal situation (Figures 1a to
1d). Treatment with Wort or LY did not induce cell death by
themselves, whereas when combined with anti-Fas they
significantly increased the apoptotic rate when compared
with anti-Fas alone, as has been shown in our previous
work [14] (Figures 1a to 1d).
Connection between the intrinsic and extrinsic apoptotic 
pathways in RA FLS
There is some indication that RA FLS are type II cells in
relation to apoptosis because Bid was cleaved after anti-Fas
stimulation [24]. We have confirmed these results showing
that after incubation with anti-Fas the detectable full Bid
protein is significantly decreased in all RA FLS lines analy-
sed (Figure 2a). Furthermore, we wanted to know whether
the cleavage of Bid is essential for apoptosis in RA FLS. To
this end, Bid was suppressed in RA FLS from five different
patients and the efficiency of Bid silencing is shown in Fig-
ures 2b and 2c. Interestingly, suppression of Bid completely
abrogated Fas-induced apoptosis (Figure 2d). In contrast,
transfection with control siRNA did not alter Fas-induced
apoptosis, indicating the relevance of the Bid protein in
apoptosis induced by anti-Fas, and consequently the con-
nection between intrinsic and extrinsic pathways.
Regulation of Bid cleavage by the PI3K/Akt pathway
Given the above results, it seemed possible that RA FLS
could resemble human prostate cancer lines, in which the
PI3K/Akt pathway interferes with TRAIL-mediated apop-
tosis by inhibiting the cleavage of Bid [29,30]. To test
whether a similar mechanism was at play in RA FLS, we
analysed the effect of Akt inhibition on Bid expression. For
this, RA FLS from six different patients were treated with
the PI3 kinase inhibitor Wort for one hour before the addi-
tion of anti-Fas antibody. As shown in Figure 3, this treat-
ment significantly reduced the level of Akt phosphorylation
and markedly increased the cleavage of Bid in comparison
to that observed after anti-Fas alone. This later effect was
demonstrated by a marked reduction of cellular Bid protein
expression.
Relevance of Bid cleavage for Akt contribution to Fas-
induced apoptosis resistance
To further assess the contribution that regulation of Bid
cleavage by Akt has on the Fas-mediated resistance to
apoptosis in RA FLS, we used siRNA suppression of Bid.
RA FLS non-transfected and transfected with control or BidGarcía et al. Arthritis Research & Therapy 2010, 12:R33
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siRNA were pre-treated with the PI3 kinase inhibitors LY
or Wort before Fas stimulation and apoptosis rate was
determined (Figure 2d). Neither treatment with LY nor
treatment with Wort alone induced apoptosis in RA FLS,
whereas Fas stimulation after pre-treatment with any of
these two inhibitors induced significant apoptosis compared
with Fas-only treatment. The same result was observed in
cells transfected with control siRNA, but not in cells trans-
fected with the specific Bid siRNA, where full resistance to
Fas-induced apoptosis was found both with and without
Wort treatment.
Bid availability limits Fas-induced apoptosis in RA FLS
The high cleavage of Bid shown after blocking Akt phos-
phorylation was accompanied by a modest increase in Fas-
induced apoptosis. We wondered whether availability of
Bid could limit the extent of apoptosis in a way reminiscent
of the resistance mediated by increased expression of anti-
apoptotic molecules [6-11]. To test this possibility, cells
from six different patients were transiently transfected with
full-length Bid vector (pDs Red2-Bid) or pDsRed2 control
vector. The efficiency of transfection was analysed by
immunofluorescence assays and western blot as shown in
Figures 4a and 4b. As observed in Figure 4c, the treatment
with Wort alone did not alter cell viability. Interestingly,
Bid overexpression highly increased Fas-induced apoptosis
compared with cells transfected with pDs2Red2 control
vector (P = 0.01, Figure 4c), indicating that the amount of
Bid contributed to resistance to apoptosis. Pre-treatment
with Wort further sensitizes to apoptosis the Bid-overex-
pressing FLS cells, indicating that in spite of the high levels
of Bid, they were still regulated by phosphorylated Akt.
Finally, to test whether the mitochondrial pathway is the
only one involved in these effects, we used the caspase-9
Figure 1 PI3 kinase inhibition sensitizes RA FLS to Fas-induced apoptosis. Cultured rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) 
were untreated (Basal), treated for 12 hours with 1 μg/ml anti-Fas antibody or pretreated for one hour with phosphoinositol-3 (PI3) kinase inhibitors 
(Wortmannine (Wort) or LY294002 (LY)) before Fas stimulation. (a) Apopotosis was quantified by nucleosomal release ELISA assay. Changes in individ-
ual RA FLS lines are represented. * indicates P < 0.05 versus untreated cells; # indicates P < 0.01 versus anti-Fas-only treated cells. (b) Caspase 3/7 activity 
determined by a caspase 3/7-Glo assay. (c) Quantification of apoptosis in RA FLS by Hoetchst 33258 staining. For b and c, results are the mean (stan-
dard error of the mean) of six different RA FLS lines. * indicates P < 0.05 versus untreated cells and # indicates P < 0.05 versus anti-Fas-only treated cells. 
(d) Representative images of one experiment are shown.
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inhibitor, Z-LE(Ome)HD(Ome)-FMK (LEHD) before Fas
stimulation. Treatment of cells with LEHD alone had no
effect on cell viability. However, as shown in Figure 4c,
caspase-9 inhibition completely blocked apoptosis induced
by treatment with anti-Fas and Wort even in Bid transfected
cells. This was shown by the apoptotic rate that decreased
near to basal levels in all RA FLS groups.
It has been recently described that memFasL stimulation
leads to more effective apoptosis than anti-Fas antibody due
to different organization of DISC, leading to more efficient
caspase-8 activation [33]. Then, to exclude that the Bid
requirement in Fas-mediated apoptosis of RA FLS was
linked to signalling with anti-Fas antibody, apoptosis was
induced by treatment with memFasL. RA FLS from seven
patients were treated with 1, 10 or 100 ng/ml mFasL and
the 100 ng/ml was chosen as the most efficient (not shown).
As shown in Figure 5a, induction of apoptosis was similar
to that obtained after treatment with anti-Fas antibody.
These results confirm that Bid is a limiting factor in Fas-
mediated apoptosis of RA FLS under a more physiological
stimulus.
We also explored by western blot the expression of cas-
pase-9 in Bid-overexpressing and parental RA FLS after
treatment with anti-Fas or anti-Fas and Wort (Figures 5b
and 5c). Our results showed that PI3 kinase inhibition pro-
motes caspase-9 cleavage that was significantly more
marked in overexpressing FLS treated with Bid, confirming
the mitochondrial pathway involvement.
Discussion
Resistance of RA FLS to Fas-mediated apoptosis is of great
interest not only from a scientific point of view but also for
its practical implications. The synovial hyperplasia charac-
teristic of RA is facilitated by the resistance of FLS to apop-
Figure 2 Effect of Bid suppression on Fas-induced apoptosis of RA FLS. (a) Cultured fibroblast-like synoviocytes (FLS) from five rheumatoid ar-
thritis (RA) patients were incubated with 1 μg/ml of anti-Fas antibody and Bid expression was assessed by western blot. A representative blot is shown. 
(b and c) RA FLS were either non-transfected or transfected with Bid or control small interfering RNA (siRNA). Proteins were extracted 48 hours after 
transfection and western blot was performed. (b) Densitometric analysis of band intensities normalized to the actin band is shown. Data are the mean 
(standard error of the mean (SEM)) of five different RA FLS lines. * indicates P < 0.05. (c) A representative blot is shown. (d) Forty-eight hours after trans-
fection, RA FLS were left untreated (Basal), treated for 12 hours with 1 μg/ml anti-Fas antibody or pretreated for one hour with Wortmannine (Wort) 
or LY294002 (LY) before Fas stimulation. Apoptosis was determined by quantification of nucleosomal release. Results are the mean (SEM) of six differ-
ent RA FLS lines. * indicates P < 0.05 versus basal; and # indicates P < 0.05 versus anti-Fas-only treatment.
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tosis. It has been demonstrated that only a small percentage
of cultured FLS undergo apoptosis after Fas stimulation
despite their expression of functional Fas. Furthermore, ex
vivo  studies of RA synovial tissues show that apoptotic
cells are rare, although Fas receptors in FLS and its ligand
in co-localized macrophages and T cells are seen [34,35].
Therefore, to elucidate the molecular mechanisms of this
resistance to apoptosis, and to clarify the steps of the Fas
pathway in this specific type of cells is required. Our exper-
iments confirm that RA FLS are type II cells, in which
death receptor-induced apoptosis requires activation of the
mitochondrial pathway through Bid cleavage. This has
already been suggested in a previous work [24]. We have
also shown that constitutive Akt phosphorylation mediates
the resistance to Fas-induced apoptosis in these cells. Inter-
estingly, the effect is mediated by inhibition of the cleavage
of Bid. Further to this finding, we have demonstrated that
depletion of Bid by RNA interference leads to a complete
resistance to Fas-mediated apoptosis in RA FLS, indicating
that apoptosis signalling through Fas occurs exclusively in
a Bid-dependent way. Substantiation of the role of Bid in
the Fas-induced apoptosis was obtained by transfection of
RA FLS with the full-length Bid vector.
Additional evidence for the involvement of the intrinsic
pathway in Fas-induced apoptosis was gathered by the
experiments of inhibition of caspase-9. Direct activation of
caspase-3 by caspase-8 seemed insufficient to RA FLS cell
death. Therefore, our results demonstrated the connection
between the intrinsic and extrinsic apoptotic pathways in
Fas-mediated apoptosis in RA FLS cells. In mice, Scatizzi
and colleagues recently showed the importance of Bid for
arthritis [23]. In K/BxN serum transfer-induced arthritis,
mice lacking Bid developed severe arthritis and joint
destruction. Synovial analysis showed fewer apoptotic cells
in Bid-deficient mice than in control mice [23].
In addition, our work points to the PI3 kinase/Akt path-
way as a novel molecular mechanism explaining the Fas-
mediated resistance in RA FLS. Previous observations in
RA FLS and other cell types are alike [12-14,29,30]. In RA
FLS, Zhang and colleagues [13] reported that inhibition of
Figure 3 PI3 kinase inhibition increases Bid cleavage. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) were left untreated (Basal) or 
treated for 12 hours with 1 μg/ml anti-Fas antibody or pretreated for one hour with phosphoinositol-3 (PI3) kinase inhibitor Wortmannine (Wort) be-
fore Fas stimulation. Expression of (a) phosphoAkt and (b) Bid was analysed by western blot. Data are expressed as mean (standard error of the mean) 
of FLS from six different RA patients. * indicates P < 0.05, ** indicates P < 0.01 and *** indicates P < 0.001. (c) A representative blot is shown.
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endogenous Akt phosphorylation sensitized RA FLS to
TNF-induced apoptosis. Moreover, Miyashita and col-
leagues [12] showed that Akt inhibition by siRNA technol-
ogy significantly increased TRAIL-mediated apoptosis in
RA FLS. However, the molecular mechanism has not been
investigated. Recently, Audo and colleagues [36] have
shown that inhibition of PI3 kinase/Akt pathway sensitizes
RA FLS to TRAIL-induced apoptosis by reduction of
expression of the anti-apoptotic proteins Mcl-1, XIAP, and
RIP, and increase of the cell cycle inhibitor p21. Of interest
in our work is that the Akt-dependent resistance to apopto-
sis is due to its inhibition of Bid cleavage in RA FLS cells.
Therefore, Akt links the death receptor and the mitochon-
drial pathways in these cells. This mechanism of resistance
to apoptosis has been previously reported in prostate cancer
cells [29,30]. Although it is unknown how Akt regulates
Bid cleavage, it is conceivable that activated Akt could
phosphorylate Bid, inhibiting its cleavage by caspase-8.
Indeed, it has been demonstrated that phosphorylation of
Thr59, a residue localized near to the caspase-8 cleavage
site, inhibits Bid cleavage by this caspase [37].
However, Akt inhibits apoptosis through several other
mechanisms including activation of nuclear factor-kB,
phosphorylation of Bad, Bax, and inhibition of pro-apop-
totic p53 [25,26,28,38]. It seems that different cells types
have different mechanisms leading to the Akt-dependent
resistance to apoptosis.
Conclusions
Our results show, for the first time, that endogenous phos-
phorylation of Akt protects RA FLS against the apoptosis
induced by Fas through inhibition of Bid cleavage and point
to PI3 kinase/Akt pathway as potential therapeutic target in
RA.
In summary, this study demonstrates the essential role of
the mitochondrial pathway in Fas-mediated apoptosis of
Figure 4 Effect of Bid overexpression on anti-Fas induced apoptosis of RA FLS. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) were 
transfected with pDsRed2-Bid or pDsRed2 control vector, 48 hours after transfection Bid expression was analysed by (a) immunofluorescence and (b) 
western blot. Representative experiments are shown. (c) After transfection, cells were left untreated (Basal) or treated for 12 hours with 1 μg/ml anti-
Fas antibody or pretreated for one hour with Wortmannine (Wort) or with Wort and the caspase-9 inhibitor, Z-LE(OMe) HD (O Me) FMK (LEHD), before 
Fas stimulation. Apoptosis was analysed by ELISA. Data are the mean (standard error of the mean) of six RA FLS lines. * indicates P < 0.05 versus basal, 
# indicates P < 0.05 versus anti-Fas-only treatment and † indicates P < 0.05 versus anti-Fas and Wort treatment.
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RA FLS and describes a new molecular mechanism of this
apoptosis resistance.
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Figure 5 Bid overexpression highly increases the apoptosis induced in RA FLS by membrane-bound FasL and caspase-9 cleavage after 
anti-Fas stimulation. (a) Cultured rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) were transfected as indicated in Figure 4 and treated for 
12 hours with 100 ng/ml mFasL or pretreated for one hour with Wortmannine (Wort) or with Wort and the caspase-9 inhibitor, Z-LE(OMe) HD (O Me) 
FMK (LEHD), before Fas stimulation. Apoptosis, assessed by quantification of nucleosomal release, is shown and data represented the mean (standard 
error of the mean) of seven RA FLS different lines. (b and c) Transfected RA FLS were treated for 12 hours with 1 μg/ml anti-Fas antibody or pretreated 
for one hour with Wort before Fas stimulation. Caspase-9 cleavage was analysed by western blot. (b) A representative blot is shown. (c) Densitometric 
analysis of band intensity of cleaved caspase-9 normalized to full caspase-9 is shown. * indicates P < 0.05; # and † indicate P < 0.05 versus anti-Fas-only 
treatment.
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